Showing results (101-110 of 120) with videos related to
Sort By:
Pageof 12
Pancreas|April 19, 2011
RUNX1T1: a novel predictor of liver metastasis in primary pancreatic endocrine neoplasmsAejaz Nasir, James Helm, Leslie Turner, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2020
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 StudyJonathan Strosberg, Nobumasa Mizuno, Toshihiko Doi, et al.Endocrine-Related Cancer|September 13, 2023
A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumorsSonia M Abuzakhm, Vineeth Sukrithan, Briant Fruth, et al.The Oncologist|December 10, 2020
Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is ≥10%?Elettra Merola, Teresa Alonso Gordoa, Panpan Zhang, et al.Cancer Science|October 22, 2017
Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysisNicola Fazio, Roberto Buzzoni, Gianfranco Delle Fave, et al.Endocrine-Related Cancer|January 22, 2021
Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasmsJames C Yao, Jonathan Strosberg, Nicola Fazio, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2015
Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumorsAdil I Daud, Michelle T Ashworth, Jonathan Strosberg, et al.Pancreas|December 6, 2012
Systemic treatment in unresectable metastatic well-differentiated carcinoid tumors: consensus results from a modified delphi processJonathan R Strosberg, George A Fisher, Al B Benson, et al.Neuroendocrinology|May 30, 2017
Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown PrimarySimron Singh, Carlo Carnaghi, Roberto Buzzoni, et al.JAMA Oncology|July 29, 2018
Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine TumorsSimron Singh, Lesley Moody, David L Chan, et al.Pageof 12